Skip to main content
. Author manuscript; available in PMC: 2011 Jan 15.
Published in final edited form as: J Immunol. 2009 Dec 4;184(2):746–756. doi: 10.4049/jimmunol.0902962

Figure 7.

Figure 7

MAPK kinase pathways in HIV-1ADA infected human MDM treated with CEP-1347. Human monocytes collected after centrifugal elutriation were cultured for seven days in 1,000 U/ml MCSF then infected with HIV-1ADA viral stock at an MOI of 0.01 for 6 h with/out 220 nM CEP-1347. CEP-1347 was continued through the experiment. Uninfected MDM with or without CEP-1347 was used as controls. Viral replication continued for 5 days. Viral infection at 5 days showed RT activity 10-fold above background levels. Replicate control and HIV-1 infected MDM were treated with LPS at 100 ng/ml for 24 h when all cells were harvested for Western blot assays. Cell lysates were analyzed using Abs specific MLK3, phospho-MLK3, ERK1/2, phospho-ERK1/2, p38, phospho-p38, JNK and phospho-JNK. The data presented here is a representative of four independent experiments.